[HTML][HTML] The development of COVID-19 treatment

Y Yuan, B Jiao, L Qu, D Yang, R Liu - Frontiers in immunology, 2023 - frontiersin.org
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused
a pandemic named coronavirus disease 2019 (COVID-19) that has become the greatest …

Recent developments in the immunopathology of COVID‐19

H Zhang, Y Sun, Y Wang, D Yazici, D Azkur, I Ogulur… - Allergy, 2023 - Wiley Online Library
There has been an important change in the clinical characteristics and immune profile of
Coronavirus disease 2019 (COVID‐19) patients during the pandemic thanks to the …

[HTML][HTML] Rhinovirus-induced epithelial RIG-I inflammasome suppresses antiviral immunity and promotes inflammation in asthma and COVID-19

U Radzikowska, A Eljaszewicz, G Tan… - Nature …, 2023 - nature.com
Rhinoviruses and allergens, such as house dust mite are major agents responsible for
asthma exacerbations. The influence of pre-existing airway inflammation on the infection …

[HTML][HTML] Post-COVID-19 syndrome comprehensive assessment: from clinical diagnosis to imaging and biochemical-guided diagnosis and management

MZ Yan, M Yang, CL Lai - Viruses, 2023 - mdpi.com
The COVID-19 outbreak was first reported in 2019, causing massive morbidity and mortality.
The majority of the COVID-19 patients survived and developed Post-COVID-19 Syndrome …

[HTML][HTML] Effect of asthma, COPD, and ACO on COVID-19: A systematic review and meta-analysis

Y Uruma, T Manabe, Y Fujikura, M Iikura, M Hojo… - PLoS …, 2022 - journals.plos.org
Introduction The prevalence of asthma, chronic obstructive pulmonary disease (COPD), and
asthma-COPD overlap (ACO) in patients with COVID-19 varies, as well as their risks of …

[HTML][HTML] Interferon gamma-1b for the prevention of hospital-acquired pneumonia in critically ill patients: a phase 2, placebo-controlled randomized clinical trial

A Roquilly, B Francois, O Huet, Y Launey… - Intensive Care …, 2023 - Springer
Purpose We aimed to determine whether interferon gamma-1b prevents hospital-acquired
pneumonia in mechanically ventilated patients. Methods In a multicenter, placebo …

Inhaled corticosteroids for the treatment of COVID-19

M Bafadhel, R Faner, C Taillé… - European …, 2022 - Eur Respiratory Soc
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has caused
severe illness and mortality for millions worldwide. Despite the development, approval and …

Multiplex hybrid antigen-capture LC-MRM quantification in sera and nasal lining fluid of AZD7442, a SARS-CoV-2-targeting antibody combination

R Mu, Y Huang, J Bouquet, J Yuan, RJ Kubiak… - Analytical …, 2022 - ACS Publications
AZD7442 (tixagevimab [AZD8895]/cilgavimab [AZD1061]) is a monoclonal antibody (mAb)
combination in development for the prevention and treatment of coronavirus disease 2019 …

[HTML][HTML] Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial

JW Eikelboom, SS Jolly, EP Belley-Cote… - The Lancet …, 2022 - thelancet.com
Background The large number of patients worldwide infected with the SARS-CoV-2 virus
has overwhelmed health-care systems globally. The Anti-Coronavirus Therapies (ACT) …

[HTML][HTML] Analysis of plasma proteins involved in inflammation, immune response/complement system, and blood coagulation upon admission of COVID-19 patients to …

DC Di Flora, A Dionizio, HABS Pereira, TF Garbieri… - Cells, 2023 - mdpi.com
The development of new approaches allowing for the early assessment of COVID-19 cases
that are likely to become critical and the discovery of new therapeutic targets are urgently …